Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Peer Review reports

Original Submission
28 Mar 2022	Submitted	Original manuscript
3 Apr 2022	Reviewed	Reviewer Report
14 Apr 2022	Reviewed	Reviewer Report - Eleonora De Matteis
28 Apr 2022	Author responded	Author comments - Armin Scheffler
Resubmission - Version 2
28 Apr 2022	Submitted	Manuscript version 2
Publishing
30 Apr 2022	Editorially accepted
11 May 2022	Article published	10.1186/s10194-022-01426-8

Back to article page